Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer

Armando Santoro, R. Cavina, F. Latteri, P. A. Zucali, V. Ginanni, E. Campagnoli, B. Ferrari, E. Morenghi, V. Pedicini, M. Roncalli, M. Alloisio, G. Ravasi, H. J. Soto Parra

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well tolerated, with evidence of tumor regression in patients with advanced non-small-cell lung cancer (NSCLC). Therefore, we aimed to assess the antitumor activity and tolerability of gefitinib in a series of patients with previously treated, advanced NSCLC, as a part of a compassionate use program. Patients and methods: To be eligible, all patients were required to have histologically or cytologically proven advanced or metastatic NSCLC, prior chemotherapy with at least one cisplatin-containing chemotherapy regimen or contraindication to cytotoxic drugs, Eastern Cooperative Oncology Group performance status ≤2, and adequate hematological, renal and hepatic parameters. All patients provided signed informed consent. Patient re-evaluation was performed every 4-6 weeks. Results: Seventy-three consecutive patients were enrolled. Response rate, including complete and partial response, was 9.6%; an additional 43.8% of patients achieved stable disease, for an overall disease control of 53.4%. EGFR1 status was evaluated by immunocytochemistry in 25 patients. According to EGFR1 immuno-reactivity all responses were observed with medium/strong imunoreactivity while three out of four responses were observed in high expressive patients. Median survival for all patients was 4 months while it reached 6 months for patients with disease control. The 1-year survival rate was 13.1% for the entire series and 23.2% for patients with disease control. Non-hematological toxicity was generally mild. Conclusion: Gefitinib has promising activity with a good toxicity profile in patients with progressive NSCLC who have received one or two prior chemotherapy regimens. A possible relationship within response and EGFR1 expression is suggested.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalAnnals of Oncology
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Non-Small Cell Lung Carcinoma
gefitinib
Drug Therapy
Compassionate Use Trials
Informed Consent
Protein-Tyrosine Kinases
Cisplatin
Survival Rate
Immunohistochemistry

Keywords

  • Epidermal growth factor receptor
  • Gefitinib
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer. / Santoro, Armando; Cavina, R.; Latteri, F.; Zucali, P. A.; Ginanni, V.; Campagnoli, E.; Ferrari, B.; Morenghi, E.; Pedicini, V.; Roncalli, M.; Alloisio, M.; Ravasi, G.; Soto Parra, H. J.

In: Annals of Oncology, Vol. 15, No. 1, 01.2004, p. 33-37.

Research output: Contribution to journalArticle

@article{16a3bea2be8641c6852a0c85bc28c65a,
title = "Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer",
abstract = "Background: Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well tolerated, with evidence of tumor regression in patients with advanced non-small-cell lung cancer (NSCLC). Therefore, we aimed to assess the antitumor activity and tolerability of gefitinib in a series of patients with previously treated, advanced NSCLC, as a part of a compassionate use program. Patients and methods: To be eligible, all patients were required to have histologically or cytologically proven advanced or metastatic NSCLC, prior chemotherapy with at least one cisplatin-containing chemotherapy regimen or contraindication to cytotoxic drugs, Eastern Cooperative Oncology Group performance status ≤2, and adequate hematological, renal and hepatic parameters. All patients provided signed informed consent. Patient re-evaluation was performed every 4-6 weeks. Results: Seventy-three consecutive patients were enrolled. Response rate, including complete and partial response, was 9.6{\%}; an additional 43.8{\%} of patients achieved stable disease, for an overall disease control of 53.4{\%}. EGFR1 status was evaluated by immunocytochemistry in 25 patients. According to EGFR1 immuno-reactivity all responses were observed with medium/strong imunoreactivity while three out of four responses were observed in high expressive patients. Median survival for all patients was 4 months while it reached 6 months for patients with disease control. The 1-year survival rate was 13.1{\%} for the entire series and 23.2{\%} for patients with disease control. Non-hematological toxicity was generally mild. Conclusion: Gefitinib has promising activity with a good toxicity profile in patients with progressive NSCLC who have received one or two prior chemotherapy regimens. A possible relationship within response and EGFR1 expression is suggested.",
keywords = "Epidermal growth factor receptor, Gefitinib, Non-small-cell lung cancer",
author = "Armando Santoro and R. Cavina and F. Latteri and Zucali, {P. A.} and V. Ginanni and E. Campagnoli and B. Ferrari and E. Morenghi and V. Pedicini and M. Roncalli and M. Alloisio and G. Ravasi and {Soto Parra}, {H. J.}",
year = "2004",
month = "1",
doi = "10.1093/annonc/mdh010",
language = "English",
volume = "15",
pages = "33--37",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer

AU - Santoro, Armando

AU - Cavina, R.

AU - Latteri, F.

AU - Zucali, P. A.

AU - Ginanni, V.

AU - Campagnoli, E.

AU - Ferrari, B.

AU - Morenghi, E.

AU - Pedicini, V.

AU - Roncalli, M.

AU - Alloisio, M.

AU - Ravasi, G.

AU - Soto Parra, H. J.

PY - 2004/1

Y1 - 2004/1

N2 - Background: Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well tolerated, with evidence of tumor regression in patients with advanced non-small-cell lung cancer (NSCLC). Therefore, we aimed to assess the antitumor activity and tolerability of gefitinib in a series of patients with previously treated, advanced NSCLC, as a part of a compassionate use program. Patients and methods: To be eligible, all patients were required to have histologically or cytologically proven advanced or metastatic NSCLC, prior chemotherapy with at least one cisplatin-containing chemotherapy regimen or contraindication to cytotoxic drugs, Eastern Cooperative Oncology Group performance status ≤2, and adequate hematological, renal and hepatic parameters. All patients provided signed informed consent. Patient re-evaluation was performed every 4-6 weeks. Results: Seventy-three consecutive patients were enrolled. Response rate, including complete and partial response, was 9.6%; an additional 43.8% of patients achieved stable disease, for an overall disease control of 53.4%. EGFR1 status was evaluated by immunocytochemistry in 25 patients. According to EGFR1 immuno-reactivity all responses were observed with medium/strong imunoreactivity while three out of four responses were observed in high expressive patients. Median survival for all patients was 4 months while it reached 6 months for patients with disease control. The 1-year survival rate was 13.1% for the entire series and 23.2% for patients with disease control. Non-hematological toxicity was generally mild. Conclusion: Gefitinib has promising activity with a good toxicity profile in patients with progressive NSCLC who have received one or two prior chemotherapy regimens. A possible relationship within response and EGFR1 expression is suggested.

AB - Background: Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well tolerated, with evidence of tumor regression in patients with advanced non-small-cell lung cancer (NSCLC). Therefore, we aimed to assess the antitumor activity and tolerability of gefitinib in a series of patients with previously treated, advanced NSCLC, as a part of a compassionate use program. Patients and methods: To be eligible, all patients were required to have histologically or cytologically proven advanced or metastatic NSCLC, prior chemotherapy with at least one cisplatin-containing chemotherapy regimen or contraindication to cytotoxic drugs, Eastern Cooperative Oncology Group performance status ≤2, and adequate hematological, renal and hepatic parameters. All patients provided signed informed consent. Patient re-evaluation was performed every 4-6 weeks. Results: Seventy-three consecutive patients were enrolled. Response rate, including complete and partial response, was 9.6%; an additional 43.8% of patients achieved stable disease, for an overall disease control of 53.4%. EGFR1 status was evaluated by immunocytochemistry in 25 patients. According to EGFR1 immuno-reactivity all responses were observed with medium/strong imunoreactivity while three out of four responses were observed in high expressive patients. Median survival for all patients was 4 months while it reached 6 months for patients with disease control. The 1-year survival rate was 13.1% for the entire series and 23.2% for patients with disease control. Non-hematological toxicity was generally mild. Conclusion: Gefitinib has promising activity with a good toxicity profile in patients with progressive NSCLC who have received one or two prior chemotherapy regimens. A possible relationship within response and EGFR1 expression is suggested.

KW - Epidermal growth factor receptor

KW - Gefitinib

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=9144244180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144244180&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh010

DO - 10.1093/annonc/mdh010

M3 - Article

C2 - 14679116

AN - SCOPUS:9144244180

VL - 15

SP - 33

EP - 37

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -